Zetomipzomib
- Generic Name
- Zetomipzomib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H42N4O8
- CAS Number
- 1629677-75-3
- Unique Ingredient Identifier
- O4BT6C02M2
- Background
Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).
- Associated Conditions
- -
- Associated Therapies
- -
Kezar Life Sciences suspends subject enrolment in trial of lupus nephritis drug
Kezar Life Sciences suspended PALIZADE trial of zetomipzomib for lupus nephritis after IDMC safety review, reporting 4 fatal SAEs with similar symptoms near dosing time.
Kezar Study Evaluates Potential New Treatment for People with Lupus Nephritis
PALIZADE is a Phase 2b, randomized, controlled, double-blind, multicenter study evaluating the efficacy and safety of zetomipzomib (KZR-616) 30 mg or 60 mg vs. placebo in patients with active lupus nephritis. Sponsored by Kezar Life Sciences, it involves screening, 52 weeks of treatment, and a follow-up visit. Participants must meet specific criteria, including age, biopsy results, and lab values, and cannot have certain medical conditions or received specific treatments. The study is placebo-controlled, double-blind, and conducted globally.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath